← All trials
NCT03162653
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2017
- Primary completion
- Nov 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 846
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of TuebingenLead sponsor
- Katholieke Universiteit LeuvenCollaborator
- University of ZurichCollaborator
- Osaka UniversityCollaborator
- Utrecht UniversityCollaborator
- University of OstravaCollaborator
- Technical University of DresdenCollaborator
- University of ValenciaCollaborator
- University of HelsinkiCollaborator
- University of PortoCollaborator
- University of ViennaCollaborator
- Helsingin Ja Uudenmaan SairaanhoitopiirinCollaborator
- ACE Pharmaceuticals BVCollaborator
- Aarhus UniversityCollaborator
- Poznan UniversityCollaborator
- University of TuebingenStudy director
- Technical University of DresdenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.